Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 1/20 | 0.45 |
| ▸ | GCK | P35557 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | GRM5 | P41594 | 3/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL839791 | 1.00 | FFAR2 (0.45) | FFAR2GCKALDH1A1RAB9AKCNH2 | |
| SCHEMBL840526 | 0.88 | RAB9A (0.45) | GCKALDH1A1RAB9AKCNH2L3MBTL1 | |
| SCHEMBL840527 | 0.88 | RAB9A (0.45) | GCKALDH1A1RAB9AKCNH2L3MBTL1 | |
| SCHEMBL850246 | 0.87 | L3MBTL1 (0.51) | ALDH1A1RAB9AMAPK1L3MBTL1TDP1 | |
| SCHEMBL839642 | 0.87 | L3MBTL1 (0.51) | ALDH1A1RAB9AMAPK1L3MBTL1TDP1 | |
| SCHEMBL839643 | 0.87 | L3MBTL1 (0.51) | ALDH1A1RAB9AMAPK1L3MBTL1TDP1 | |
| SCHEMBL838668 | 0.84 | KCNH2 (0.42) | GCKKCNH2IDO1 | |
| SCHEMBL838667 | 0.84 | KCNH2 (0.42) | GCKKCNH2IDO1 | |
| SCHEMBL840139 | 0.82 | POLB (0.48) | FFAR2ALDH1A1RAB9AKDM4ENPC1 | |
| SCHEMBL839005 | 0.82 | NOTUM (0.38) | GCKKCNH2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | GCK, GCKR, GPR119 | FFAR2 1155/4885GCK 1/4885ALDH1A1 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.